Revenue growth of drug firms in current fiscal to be in the range of 7-9 pc: Icra

“Revenue growth for ICRA sample set (21 companies) is estimated at 7-9 per cent in FY2022 and 8-11 per cent in FY2023, supported by gradual recovery post the initial impact of Covid-19,” Icra Vice President & Sector Head Gaurav Jain said in a statement.